Osemozotan

Osemozotan
IUPAC ime
	5-(3-[((2S)-1,4-benzodioksan-2-ilmetil)amino]propoksi)-1,3-benzodioksol
Pravni status
Pravni status	Nije kontrolisana supstanca;
Identifikatori
CAS broj	137275-80-0
ATC kod	none
PubChem	CID 198746
UNII	M65825806Q
Hemijski podaci
Formula	C20H23NO4
Molarna masa	341,400 g/mol
	SMILES c4cc1OCOc1cc4OCCCNCC3CCc2ccccc2O3; ;

Osemozotan (MKC-242) je selektivni agonist 5-HT_1A receptora sa funkcionalnom selektivnošću. On deluje kao pun agonist na presinaptičkim i kao parcijalni agonist na postsinaptičkim 5-HT_1A receptorima.^[1] On pokazuje antidepresivne i anksiolitske efekte u životinjskim studijama.^[2]^[3] Osemozotan se koristi za istraživanje uloge 5-HT_1A receptora u modulaciji otpuštanja dopamina i serotonina u mozgu,^[4]^[5] i njihovog učešća u adikciji na zloupotrebljene stimulante kao što su kokain i metamfetamin.^[6]^[7]^[8]^[9]^[10]

Reference[уреди | уреди извор]

^ Matsuda, T.; Yoshikawa, T.; Suzuki, M.; Asano, S.; Somboonthum, P.; Takuma, K.; Nakano, Y.; Morita, T.; Nakasu, Y. (1995). „Novel benzodioxan derivative, 5-(3-((2S)-1,4-benzodioxan-2- ylmethyl)aminopropoxy)-1,3-benzodioxole HCl (MKC-242), with a highly potent and selective agonist activity at rat central serotonin1A receptors”. Japanese journal of pharmacology. 69 (4): 357—366. PMID 8786639. doi:10.1254/jjp.69.357.
^ Abe, M.; Tabata, R.; Saito, K.; Matsuda, T.; Baba, A.; Egawa, M. (1996). „Novel benzodioxan derivative, 5-3-((2S)-1,4-benzodioxan-2-ylmethyl) aminopropoxy-1,3-benzodioxole HCl (MKC-242), with anxiolytic-like and antidepressant-like effects in animal models”. The Journal of Pharmacology and Experimental Therapeutics. 278 (2): 898—905. PMID 8768745.
^ Sakaue, M.; Ago, Y.; Sowa, C.; Koyama, Y.; Baba, A.; Matsuda, T. (2003). „The 5-HT1A receptor agonist MKC-242 increases the exploratory activity of mice in the elevated plus-maze”. European Journal of Pharmacology. 458 (1–2): 141—144. PMID 12498918. doi:10.1016/S0014-2999(02)02786-3.
^ Sakaue, M.; Somboonthum, P.; Nishihara, B.; Koyama, Y.; Hashimoto, H.; Baba, A.; Matsuda, T. (2000). „Postsynaptic 5-hydroxytryptamine1A receptor activation increases in vivo dopamine release in rat prefrontal cortex”. British Journal of Pharmacology. 129 (5): 1028—1034. PMC 1571922 . PMID 10696105. doi:10.1038/sj.bjp.0703139.
^ Ago, Y.; Koyama, Y.; Baba, A.; Matsuda, T. (2003). „Regulation by 5-HT1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex”. Neuropharmacology. 45 (8): 1050—1056. PMID 14614948. doi:10.1016/S0028-3908(03)00304-6.
^ Ago, Y.; Nakamura, S.; Uda, M.; Kajii, Y.; Abe, M.; Baba, A.; Matsuda, T. (2006). „Attenuation by the 5-HT1A receptor agonist osemozotan of the behavioral effects of single and repeated methamphetamine in mice”. Neuropharmacology. 51 (4): 914—922. PMID 16863654. doi:10.1016/j.neuropharm.2006.06.001.
^ Ago, Y.; Nakamura, S.; Hayashi, A.; Itoh, S.; Baba, A.; Matsuda, T. (2006). „Effects of osemozotan, ritanserin and azasetron on cocaine-induced behavioral sensitization in mice”. Pharmacology, Biochemistry, and Behavior. 85 (1): 198—205. PMID 16962650. doi:10.1016/j.pbb.2006.07.036.
^ Ago, Y.; Nakamura, S.; Baba, A.; Matsuda, T. (2008). „Neuropsychotoxicity of abused drugs: effects of serotonin receptor ligands on methamphetamine- and cocaine-induced behavioral sensitization in mice”. Journal of pharmacological sciences. 106 (1): 15—21. PMID 18198473. doi:10.1254/jphs.FM0070121.
^ Tsuchida, R.; Kubo, M.; Kuroda, M.; Shibasaki, Y.; Shintani, N.; Abe, M.; Köves, K.; Hashimoto, H.; Baba, A. (2009). „An antihyperkinetic action by the serotonin 1A-receptor agonist osemozotan co-administered with psychostimulants or the non-stimulant atomoxetine in mice”. Journal of pharmacological sciences. 109 (3): 396—402. PMID 19270432. doi:10.1254/jphs.08297FP.
^ Tsuchida, R.; Kubo, M.; Shintani, N.; Abe, M.; Köves, K.; Uetsuki, K.; Kuroda, M.; Hashimoto, H.; Baba, A. (2009). „Inhibitory effects of osemozotan, a serotonin 1A-receptor agonist, on methamphetamine-induced c-Fos expression in prefrontal cortical neurons”. Biological & Pharmaceutical Bulletin. 32 (4): 728—731. PMID 19336914. doi:10.1248/bpb.32.728.

Vidi još[уреди | уреди извор]

Spoljašnje veze[уреди | уреди извор]

[1] Matsuda, T.; Yoshikawa, T.; Suzuki, M.; Asano, S.; Somboonthum, P.; Takuma, K.; Nakano, Y.; Morita, T.; Nakasu, Y. (1995). „Novel benzodioxan derivative, 5-(3-((2S)-1,4-benzodioxan-2- ylmethyl)aminopropoxy)-1,3-benzodioxole HCl (MKC-242), with a highly potent and selective agonist activity at rat central serotonin1A receptors”. Japanese journal of pharmacology. 69 (4): 357—366. PMID 8786639. doi:10.1254/jjp.69.357.

[2] Abe, M.; Tabata, R.; Saito, K.; Matsuda, T.; Baba, A.; Egawa, M. (1996). „Novel benzodioxan derivative, 5-3-((2S)-1,4-benzodioxan-2-ylmethyl) aminopropoxy-1,3-benzodioxole HCl (MKC-242), with anxiolytic-like and antidepressant-like effects in animal models”. The Journal of Pharmacology and Experimental Therapeutics. 278 (2): 898—905. PMID 8768745.

[3] Sakaue, M.; Ago, Y.; Sowa, C.; Koyama, Y.; Baba, A.; Matsuda, T. (2003). „The 5-HT1A receptor agonist MKC-242 increases the exploratory activity of mice in the elevated plus-maze”. European Journal of Pharmacology. 458 (1–2): 141—144. PMID 12498918. doi:10.1016/S0014-2999(02)02786-3.

[4] Sakaue, M.; Somboonthum, P.; Nishihara, B.; Koyama, Y.; Hashimoto, H.; Baba, A.; Matsuda, T. (2000). „Postsynaptic 5-hydroxytryptamine1A receptor activation increases in vivo dopamine release in rat prefrontal cortex”. British Journal of Pharmacology. 129 (5): 1028—1034. PMC 1571922 . PMID 10696105. doi:10.1038/sj.bjp.0703139.

[5] Ago, Y.; Koyama, Y.; Baba, A.; Matsuda, T. (2003). „Regulation by 5-HT1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex”. Neuropharmacology. 45 (8): 1050—1056. PMID 14614948. doi:10.1016/S0028-3908(03)00304-6.

[6] Ago, Y.; Nakamura, S.; Uda, M.; Kajii, Y.; Abe, M.; Baba, A.; Matsuda, T. (2006). „Attenuation by the 5-HT1A receptor agonist osemozotan of the behavioral effects of single and repeated methamphetamine in mice”. Neuropharmacology. 51 (4): 914—922. PMID 16863654. doi:10.1016/j.neuropharm.2006.06.001.

[7] Ago, Y.; Nakamura, S.; Hayashi, A.; Itoh, S.; Baba, A.; Matsuda, T. (2006). „Effects of osemozotan, ritanserin and azasetron on cocaine-induced behavioral sensitization in mice”. Pharmacology, Biochemistry, and Behavior. 85 (1): 198—205. PMID 16962650. doi:10.1016/j.pbb.2006.07.036.

[8] Ago, Y.; Nakamura, S.; Baba, A.; Matsuda, T. (2008). „Neuropsychotoxicity of abused drugs: effects of serotonin receptor ligands on methamphetamine- and cocaine-induced behavioral sensitization in mice”. Journal of pharmacological sciences. 106 (1): 15—21. PMID 18198473. doi:10.1254/jphs.FM0070121.

[9] Tsuchida, R.; Kubo, M.; Kuroda, M.; Shibasaki, Y.; Shintani, N.; Abe, M.; Köves, K.; Hashimoto, H.; Baba, A. (2009). „An antihyperkinetic action by the serotonin 1A-receptor agonist osemozotan co-administered with psychostimulants or the non-stimulant atomoxetine in mice”. Journal of pharmacological sciences. 109 (3): 396—402. PMID 19270432. doi:10.1254/jphs.08297FP.

[10] Tsuchida, R.; Kubo, M.; Shintani, N.; Abe, M.; Köves, K.; Uetsuki, K.; Kuroda, M.; Hashimoto, H.; Baba, A. (2009). „Inhibitory effects of osemozotan, a serotonin 1A-receptor agonist, on methamphetamine-induced c-Fos expression in prefrontal cortical neurons”. Biological & Pharmaceutical Bulletin. 32 (4): 728—731. PMID 19336914. doi:10.1248/bpb.32.728.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]